Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Clinicians in two minds over atypical antipsychotics

  • 7 Accesses

Abstract

I t’s now almost a decade since Sandoz launched the first atypical antipsychotic (clozapine) in the UK and opened a new chapter in the history of schizophrenia management. A number of other atypicals followed. These undoubtedly offer clinical benefits in this devastating disease, especially for patients who either cannot tolerate, or do not respond to, older agents.

This is a preview of subscription content, log in to check access.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Greener, M. Clinicians in two minds over atypical antipsychotics. Pharmacoecon. Outcomes News 227, 3–4 (1999). https://doi.org/10.1007/BF03294168

Download citation

Keywords

  • Schizophrenia
  • Clozapine
  • Risperidone
  • Olanzapine
  • National Health Service